SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

AbbVie Inc. – ‘8-K’ for 1/12/21

On:  Tuesday, 1/12/21, at 4:30pm ET   ·   For:  1/12/21   ·   Accession #:  1104659-21-3462   ·   File #:  1-35565

Previous ‘8-K’:  ‘8-K’ on 1/6/21 for 12/31/20   ·   Next:  ‘8-K’ on / for 2/3/21   ·   Latest:  ‘8-K’ on 2/26/24 for 2/22/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/12/21  AbbVie Inc.                       8-K:7,9     1/12/21   12:6.3M                                   Toppan Merrill/FA

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     55K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     35K 
 8: R1          Cover                                               HTML     75K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- tm212802d1_8k_htm                   XML     44K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.DEF  XBRL Definitions -- abbv-20210112_def                XML     87K 
 5: EX-101.LAB  XBRL Labels -- abbv-20210112_lab                     XML    129K 
 6: EX-101.PRE  XBRL Presentations -- abbv-20210112_pre              XML     83K 
 3: EX-101.SCH  XBRL Schema -- abbv-20210112                         XSD     19K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               30±    39K 
12: ZIP         XBRL Zipped Folder -- 0001104659-21-003462-xbrl      Zip     25K 


‘8-K’   —   Current Report


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 iX:   C:   C:   C:   C:   C:   C:   C:   C:   C: 
 i 0001551152  i false  i Common Stock, $0.01 Par Value  i ABBV 0001551152 2021-01-12 2021-01-12 0001551152 us-gaap:CommonStockMember exch:XNYS 2021-01-12 2021-01-12 0001551152 exch:XCHI us-gaap:CommonStockMember 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes0.500Percentdue2021Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.500Percentdue2023Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.375Percentdue2024Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.250Percentdue2024Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes0.750Percentdue2027Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.125Percentdue2028Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.625Percentdue2028Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes2.125Percentdue2029Member exch:XNYS 2021-01-12 2021-01-12 0001551152 abbv:SeniorNotes1.250Percentdue2031Member exch:XNYS 2021-01-12 2021-01-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM  i 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  i January 12, 2021

 

 i ABBVIE INC. 

(Exact Name of Registrant as Specified in its Charter)

_______________________________________________

 

 i Delaware    i 001-35565    i 32-0375147
(State or other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

_______________________________________________

 

 i 1 North Waukegan Road

 i North Chicago,  i Illinois  i 60064-6400

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: ( i 847)  i 932-7900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 i ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 i ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 i ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 i ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
 i Common Stock, $0.01 Par Value    i ABBV    i New York Stock Exchange
 i Chicago Stock Exchange
 i 0.500% Senior Notes due 2021    i ABBV21C    i New York Stock Exchange
 i 1.500% Senior Notes due 2023    i ABBV23B    i New York Stock Exchange
 i 1.375% Senior Notes due 2024    i ABBV24    i New York Stock Exchange
 i 1.250% Senior Notes due 2024    i ABBV24B    i New York Stock Exchange
 i 0.750% Senior Notes due 2027    i ABBV27    i New York Stock Exchange
 i 2.125% Senior Notes due 2028    i ABBV28    i New York Stock Exchange
 i 2.625% Senior Notes due 2028    i ABBV28B    i New York Stock Exchange
 i 2.125% Senior Notes due 2029    i ABBV29    i New York Stock Exchange
 i 1.250% Senior Notes due 2031    i ABBV31    i New York Stock Exchange

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  i ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 C: 

 

 

Item 7.01 Regulation FD Disclosure.

 

On January 12, 2021, AbbVie Inc. posted an investor presentation to its website at: https://investors.abbvie.com/presentations.  A copy is attached as Exhibit 99.1 to this Current Report on Form 8-K.

 

As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 and Exhibit 99.1 incorporated herein shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit
No.
  Exhibit
99.1   Investor Presentation dated January 12, 2021.
104   The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

 

 C: 
  C: 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBVIE INC.
   
Date: January 12, 2021 By: /s/ Robert A. Michael
  Name: Robert A. Michael
  Title: Executive Vice President, Chief Financial Officer

 

 C: 

 

Common Stock, $0.01 Par Value ABBV
 C: 

Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘8-K’ Filing    Date    Other Filings
Filed on / For Period end:1/12/21None on these Dates
 List all Filings 
Top
Filing Submission 0001104659-21-003462   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., Mar. 28, 4:58:19.1pm ET